ERBB2 and hepatocellular carcinoma: In addition, there are a number of dual-target and multi-target CAR-T therapies under research, such as c-Met/PD-L1 CAR-T cells for treating HCC(Fig. 6C) [85], co-express GPC3 with EGFR-targeted CAR-T treating HCC [86] Her2/B7H3 CAR-T cells treating CNS tumors [87] and so on.